Sanofi sues Novo Nordisk in the US

Sanofi has sued Novo Nordisk in the US, accusing it of false claims regarding the availability of Sanofi’s insulin drugs, Reuters reported. The Dutch company allegedly said that Sanofi’s products would no longer be available for many US patients. The complaint, filed in District Court for the District of New Jersey on Dec. 23, seeks an order forcing Novo Nordisk to pay an unspecified amount in damages and withdraw marketing materials for its product Tresiba. Specifically, the marketing materials allegedly urge doctors to switch from Sanofi’s drugs Lantus and Toujeo to Tresiba. Novo Nordisk has made no statement.
(Source Seeking Alpha)